// STATE LEGISLATION TRACKER

Kentucky HB 895 — AN ACT relating to the regulation of psychoactive substances.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Kentucky
Bill: HB 895
Filed: 2026-03-04
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Kentucky HB895 appears to focus on regulation of psychoactive substances, not peptides or routine peptide prescribing. Based only on the title, subject, and unavailable OpenStates status, it does not appear to directly affect compounded peptides, off-label peptide use, telehealth peptide clinics, NP/naturopath scope, FDA 503A/503B compounding, or PDMP rules for peptides.

Key Points

No clear peptide-specific language is available from the provided source
Title points to psychoactive substances, not compounded peptides
No known change to off-label peptide prescribing from the available info
No visible impact on telehealth peptide access or NP prescribing
No available text showing FDA 503A/503B compounding changes

What to Watch For

Note Watch for actual bill text before assuming any effect on clinics, pharmacies, or prescribers.

Concern If amendments add broad controlled-substance rules, some adjacent prescribing workflows could face more red tape.

Note Current status could not be confirmed from the provided OpenStates page.

Where the Bill Stands

The provided source did not expose a current action or bill text, so the bill's process status cannot be confirmed.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws